Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to $50.1 million.

  • Celldex Therapeutics' Total Liabilities rose 3434.57% to $50.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.1 million, marking a year-over-year increase of 3434.57%. This contributed to the annual value of $45.3 million for FY2024, which is 2435.54% up from last year.
  • Celldex Therapeutics' Total Liabilities amounted to $50.1 million in Q3 2025, which was up 3434.57% from $37.0 million recorded in Q2 2025.
  • In the past 5 years, Celldex Therapeutics' Total Liabilities ranged from a high of $50.1 million in Q3 2025 and a low of $21.8 million during Q2 2023
  • Moreover, its 5-year median value for Total Liabilities was $30.2 million (2024), whereas its average is $31.2 million.
  • As far as peak fluctuations go, Celldex Therapeutics' Total Liabilities skyrocketed by 7004.8% in 2022, and later plummeted by 4250.03% in 2023.
  • Over the past 5 years, Celldex Therapeutics' Total Liabilities (Quarter) stood at $25.2 million in 2021, then increased by 5.37% to $26.5 million in 2022, then soared by 37.41% to $36.5 million in 2023, then increased by 24.36% to $45.3 million in 2024, then rose by 10.46% to $50.1 million in 2025.
  • Its Total Liabilities was $50.1 million in Q3 2025, compared to $37.0 million in Q2 2025 and $36.5 million in Q1 2025.